Skip to main content
Type 1 diabetes screening: reframing the debate from paternalism to partnership. Reply to Scaramuzza AE, Iafusco D, Cherubini V [letter] Type 1 diabetes screening: building a clinician-patient partnership for early care of chronic beta cell failure. Reply
Safety and pharmacokinetics of teplizumab in children less than 8 years of age with stage 2 type 1 diabetes.
The power of TOPMed imputation for the discovery of Latino-enriched rare variants associated with type 2 diabetes.
Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample.
Glucose management for exercise using continuous glucose monitoring: should sex and prandial state be additional considerations? Reply to Yardley JE and Sigal RJ [letter].
Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society f
Clinical trial data validate the C-peptide estimate model in type 1 diabetes.
Beta cell function in type 1 diabetes determined from clinical and fasting biochemical variables.
Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial.
Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.